Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Coviracil license dispute

  • News

Executive Summary

Glaxo Wellcome grants full emtricitabine development rights to Triangle and Emory University under a legal dispute settlement, Triangle announced May 7. Discovered by Emory scientists, the antiviral nucleoside analogue for the treatment of HIV and hepatitis B was originally licensed to Burroughs-Wellcome. Most rights to Coviracil (formerly FTC) were returned to Emory when Glaxo acquired Burroughs-Wellcome, and were subsequently licensed to Triangle ("The Pink Sheet" April 27, 1998, p. 23). Emtricitabine is in the same class as Glaxo/BioChem's Epivir (lamivudine). The dispute settlement shifts Glaxo's remaining Coviracil property rights to Triangle, which is currently conducting Phase II/III trials in HIV and Phase I/II trials in HBV

Table

View full table

Tags:
Latest Headlines

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

See All
UsernamePublicRestriction

Register

PS034117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By